Compare Novartis AG (NVS) vs Uber Technologies Inc (UBER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Uber Technologies Inc — how do they compare? Novartis AG trades at $139.38 (market cap $262.64B), while Uber Technologies Inc trades at $71.63 (market cap $149.37B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays a 3.44% dividend while Uber Technologies Inc pays none. Which is the better fit depends on your goals.
| NVS | UBER | |
|---|---|---|
Market Cap | $262.64B | $149.37B |
Sector | Health | Industrials |
52-Week High | $168.62 | $100.10 |
52-Week Low | $121.80 | $65.94 |
Enterprise Value | $303.97B | $158.71B |
Dividend Yield | 3.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
Uber's stock trades at $71.08, down 6.18% today, amid a bearish technical signal but strong fundamentals. Revenue grew to $52.02B in 2025 with a net income of $10.05B, though Q4 2025 earnings missed expectations. Recent news highlights strategic shifts toward autonomous vehicles, including robotaxi pilots in Spain and Germany, alongside cost-cutting measures like HR layoffs and AI spending caps.
The outlook is mixed: robust revenue growth and a dominant market position support upside, but competitive pressures, regulatory risks, and a projected negative cash flow in 2026 pose challenges. Analyst consensus is strongly bullish with a $102.56 price target, suggesting significant potential if execution aligns with autonomous vehicle initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →
